Tomášková Hana, Zelená Hana, Kloudová Alena, Tomášek Ivan
Public Health Institute Ostrava, Ostrava, Czech Republic.
Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Cent Eur J Public Health. 2018 Mar;26(1):22-27. doi: 10.21101/cejph.a5251.
The aim of the serological survey of measles was to obtain information on the prevalence of antibodies against measles and to verify the effectiveness of vaccination in the Czech population in order to protect public health.
The serological survey was carried out in the Czech Republic in 2013. Antibodies against measles were tested in 3,111 serum samples of participants aged 1-64 years. Serum samples were tested for the presence of immunoglobulin G (IgG) antibodies by enzyme immunoassay (EIA). The vaccination status assessment was based on the medical documentation. Seroprevalence differences were evaluated by sex and age using the Pearson's χ test at 5% significance level.
The overall seroprevalence reached 93.0% (2,893/3,111) (95% CI 92.0-93.9). No statistically significant difference was found between men and women (p=0.724). A lower seroprevalence was identified in the first age group (1-year old children) 62% (62/100), as the vaccination has not yet been completed in this age group. The second lowest seroprevalence 80.4% (160/199) was identified in the age group of 35-44 years. The highest seroprevalence 97.7% (387/396) (95% CI 95.7-99.0) was in the population with naturally-induced immunity (age above 45 years). In the individuals with two doses seroprevalence reached 94.1% (2,081/2,212) (95% CI 93.0-95.0). The level of IgG antibodies decreased in persons above 7 years of age.
Based on the results of the serological survey carried out in 2013 in the Czech Republic, it has been decided to postpone the second MMR (measles, mumps and rubella) dose to the age of 5-6 years.
麻疹血清学调查的目的是获取有关抗麻疹抗体流行情况的信息,并验证捷克人群中疫苗接种的有效性,以保护公众健康。
2013年在捷克共和国进行了血清学调查。对3111名年龄在1至64岁的参与者的血清样本进行了抗麻疹抗体检测。通过酶免疫测定法(EIA)检测血清样本中免疫球蛋白G(IgG)抗体的存在情况。疫苗接种状况评估基于医疗记录。使用Pearson卡方检验在5%显著性水平下按性别和年龄评估血清阳性率差异。
总体血清阳性率达到93.0%(2893/3111)(95%置信区间92.0 - 93.9)。男性和女性之间未发现统计学上的显著差异(p = 0.724)。在第一个年龄组(1岁儿童)中血清阳性率较低,为62%(62/100),因为该年龄组的疫苗接种尚未完成。在35至44岁年龄组中血清阳性率第二低,为80.4%(160/199)。血清阳性率最高的是具有自然免疫的人群(45岁以上),为97.7%(387/396)(95%置信区间95.7 - 99.0)。在接种两剂疫苗的个体中血清阳性率达到94.1%(2081/2212)(95%置信区间93.0 - 95.0)。7岁以上人群中IgG抗体水平下降。
根据2013年在捷克共和国进行的血清学调查结果,已决定将第二剂MMR(麻疹、腮腺炎和风疹)疫苗接种推迟至5至6岁。